Please login to the form below

Not currently logged in
Email:
Password:

NKT-214

This page shows the latest NKT-214 news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

BMS presses go on Nektar combo pivotal trials, despite data debate

Specifically, Opdivo and NKTR-214 achieved an overall response rate (ORR) of 85% in stage 1 - i.e. ... In fact, they have data which suggests NKTR-214 can actually make PD-L1-negative tumours start expressing the biomarker.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics